#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acromegaly Henoch-Schonlein purpura Arteriovenous malformation Toxic epidermal necrolysis Glomerulonephritis Renal transplant Paraganglion neoplasm Inclusion body myositis Thymic carcinoma Angiosarcoma metastatic Ovarian cancer stage IV Ichthyosis Hypomagnesaemia Haemophilia Loeys-Dietz syndrome More trials…

    Learn about Rare Diseases

    Pleomorphic leiomyosarcoma – Diagnostics Alport’s syndrome – Life with Disease Anaplastic thyroid cancer – Life with Disease Hereditary optic atrophy – Basic Information Angelman’s syndrome – Treatment Indolent systemic mastocytosis – Diagnostics SAPHO syndrome Progressive supranuclear palsy – Trials in Disease Cholangitis sclerosing – Life with Disease Primary biliary cholangitis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Albaconazole Methylprednisolone Quemliclustat Dnth103 Istem-01 Furosemide ICOTROKINRA Adezunap Epcoritamab Nicotine Iptacopan Remifentanil Hydrochloride Crd-4730 Prilocaine Metformin Hydrochloride Ivermectin Sodium Hypochlorite SUMATRIPTAN Vilanterol Acetylcysteine More therapies…

    Learn about Your Condition

    Peptostreptococcus infection Cardiomyopathy Primary amyloidosis Pathogen resistance Myxofibrosarcoma Organ donor Plasma cell myeloma recurrent Breast angiosarcoma Basal cell naevus syndrome Loeys-Dietz syndrome Rhinitis allergic Anal cancer stage II Angiopathy Epicondylitis Hyponatraemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    Austria Belgium Denmark Estonia Finland Germany +8

  • Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Carboplatin
    • Datopotamab Deruxtecan
    • Durvalumab
    France Italy Poland Spain

  • A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Everolimus
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium France Germany Italy The Netherlands +2

  • Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Ireland +5

  • A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer stage II
    • Breast cancer stage III
    • Invasive breast carcinoma
    Investigated Drugs:
    • Zanidatamab
    • Carboplatin
    • Docetaxel
    Germany Italy Spain

  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Ivonescimab
    • Bevacizumab
    • Fluorouracil
    Belgium Czechia France Germany Hungary Italy +2

  • A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia Denmark France Germany +7

  • Comparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Cetuximab
    • Irinotecan
    Italy

  • A Study of Tulmimetostat and Luxdegalutamide Compared to Standard Treatment in Men with Advanced Prostate Cancer That No Longer Responds to Hormone Therapy

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Cabazitaxel
    • Tulmimetostat
    Denmark France Germany Italy Poland Spain

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Czechia Denmark France Germany +9
Previous Page
1 2 3 4 5 6 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!